Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
NTES-S
09999
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 115.76%87K | 74.33%-315K | 67.20%-509K | 26.78%-5.6M | -145.55%-2.26M | 78.84%-552K | -8.20%-1.23M | 49.76%-1.55M | 44.17%-7.64M | 76.32%-922K |
| Net income from continuing operations | 105.42%645K | 53.75%-1.28M | 97.70%-822K | -89.77%-67.37M | 35.11%-16.93M | -1,756.55%-11.89M | 69.72%-2.77M | -3,580.14%-35.77M | -175.20%-35.5M | -189.35%-26.09M |
| Operating gains losses | 134.43%429K | -89.89%27K | 194.37%134K | 81.68%-1.32M | 48.04%-199K | -33.69%-1.25M | 105.45%267K | 87.24%-142K | -52.98%-7.22M | 98.83%-383K |
| Depreciation and amortization | --0 | ---- | ---- | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Asset impairment expenditure | --0 | --0 | ---- | --0 | ---307K | --0 | --307K | ---- | --1.04M | --0 |
| Unrealized gains and losses of investment securities | -114.26%-1.67M | ---- | -100.15%-49K | 87.74%60.71M | -52.13%15.75M | 2,196.77%11.7M | ---- | --33.14M | --32.34M | --32.9M |
| Remuneration paid in stock | 152.87%166K | ---- | -103.56%-24K | ---- | ---- | -223.14%-314K | 335.59%278K | -35.00%674K | ---- | ---- |
| Other non cashItems | 342.74%549K | 7.37%816K | -102.77%-8K | 19.89%2.35M | 122.37%1.58M | 107.02%124K | -93.39%760K | 148.82%289K | -54.98%1.96M | ---7.08M |
| Change In working capital | -103.15%-34K | -41.23%124K | -0.76%260K | 111.48%31K | -252.66%-1.52M | 177.11%1.08M | -85.94%211K | 119.15%262K | 36.92%-270K | 3,366.30%995K |
| -Change in receivables | -6.40%190K | ---- | 951.85%690K | 111.75%67K | 23.40%-396K | 462.50%203K | 17,150.00%341K | -1,720.00%-81K | -67.16%-570K | -511.87%-517K |
| -Change in inventory | -93.75%1K | ---- | --0 | -76.65%191K | -99.48%3K | -91.62%16K | -5.88%32K | 1,066.67%140K | 149.76%818K | 45,828.85%581K |
| -Change in prepaid assets | 11.54%-276K | ---- | 19.12%162K | 190.28%223K | 139.08%208K | 13.57%-312K | 246.92%191K | -13.38%136K | 59.38%-247K | --87K |
| -Change in payables and accrued expense | -95.64%51K | ---- | -983.58%-592K | -66.05%-450K | -258.06%-1.33M | 199.91%1.17M | -122.08%-353K | 104.35%67K | -112.52%-271K | 65.52%844K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 115.76%87K | 74.33%-315K | 67.20%-509K | 26.78%-5.6M | -145.55%-2.26M | 78.83%-552K | -8.20%-1.23M | 47.95%-1.55M | 44.17%-7.64M | 76.32%-922K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 187.04%880K | 101.13%47K | 81.62%-120K | 29.47%-7.97M | 2.02%-2.13M | 51.39%-1.01M | 22.76%-4.18M | 60.11%-653K | 68.07%-11.3M | 50.08%-2.18M |
| Net intangibles purchas and sale | ---- | --0 | ---- | ---- | ---- | ---- | ---4.43M | ---- | ---- | ---- |
| Net business purchase and sale | --0 | --0 | ---- | --256K | --0 | --0 | --256K | ---- | --0 | --0 |
| Net investment purchase and sale | --0 | ---- | --0 | 27.19%-8.06M | 6.21%-1.83M | 49.13%-1.06M | -30.01%-4.43M | 81.67%-300K | 67.55%-11.08M | 74.00%-1.95M |
| Net other investing changes | 1,772.34%880K | 1,275.00%47K | 66.01%-120K | 27.75%-164K | ---304K | --47K | 99.80%-4K | ---353K | 43.39%-227K | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 187.04%880K | 101.13%47K | 81.62%-120K | 29.47%-7.97M | 2.02%-2.13M | 51.39%-1.01M | 22.76%-4.18M | 60.11%-653K | 68.07%-11.3M | 50.08%-2.18M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -2.17%-47K | 0.00%-47K | 6.38%-44K | -35.77%-186K | -2.22%-46K | 0.00%-46K | -2.17%-47K | -47K | -100.39%-137K | -22,267.49%-45K |
| Net issuance payments of debt | -2.17%-47K | 0.00%-47K | 6.38%-44K | -35.77%-186K | -2.22%-46K | 0.00%-46K | -2.17%-47K | ---47K | ---137K | ---45K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -2.17%-47K | 0.00%-47K | 6.38%-44K | -35.77%-186K | -2.22%-46K | 0.00%-46K | -2.17%-47K | ---47K | -100.39%-137K | -22,267.49%-45K |
| Net cash flow | ||||||||||
| Beginning cash position | -14.62%37.11M | -25.64%36.44M | -27.36%37.35M | -26.91%51.42M | -23.00%41.89M | -26.84%43.46M | -25.47%49.01M | -26.91%51.42M | -35.09%70.35M | -46.94%54.4M |
| Current changes in cash | 157.18%920K | 94.22%-315K | 70.12%-673K | 27.93%-13.75M | -41.32%-4.44M | 66.01%-1.61M | 17.25%-5.45M | 51.26%-2.25M | -36.78%-19.08M | 61.92%-3.14M |
| Effect of exchange rate changes | -1,182.05%-422K | 1,066.34%976K | -49.36%-233K | -302.60%-312K | -159.75%-95K | 114.77%39K | -144.30%-101K | -603.23%-156K | 112.93%154K | 115.41%159K |
| End cash Position | -10.23%37.6M | -14.62%37.11M | -25.64%36.44M | -27.36%37.35M | -27.36%37.35M | -23.00%41.89M | -26.84%43.46M | -25.47%49.01M | -44.86%51.42M | -44.86%51.42M |
| Free cash from | 115.76%87K | 94.43%-315K | 67.20%-509K | 26.78%-5.6M | -145.55%-2.26M | 78.83%-552K | -398.59%-5.65M | 47.95%-1.55M | 44.17%-7.64M | 76.32%-922K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.